<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995589</url>
  </required_header>
  <id_info>
    <org_study_id>s9acq68z</org_study_id>
    <nct_id>NCT03995589</nct_id>
  </id_info>
  <brief_title>Exercise Therapy in Patients With Peripheral Artery Disease: Evaluating the Clinical Effectiveness of Exercise Therapy and Exploring Determinants of Improvement</brief_title>
  <acronym>PROSECO</acronym>
  <official_title>Exercise Therapy in Patients With Peripheral Artery Disease: Evaluating the Clinical Effectiveness of Exercise Therapy and Exploring Determinants of Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      I. To investigate whether patient characteristics, exercise therapy characteristics, local
      metabolic exercise response, endothelial function, autonomic function or atherosclerotic
      lesion location can predict the walking response to a successfully completed semi-supervised
      exercise intervention in patients with intermittent claudication (WP I) II. To assess the
      effect of a home-based exercise intervention with remote monitoring and coaching on
      cardiovascular risk factors in patients with intermittent claudication (WP II)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain free walking distance</measure>
    <time_frame>Baseline - 12 weeks</time_frame>
    <description>Treadmill protocol</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Walking Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Walking</intervention_name>
    <description>Technology-guided semi-supervised walking therapy</description>
    <arm_group_label>Walking Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Go Home and Walk advice</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The study population will comprise patients diagnosed with lower-extremity artery disease
        (ABI ≤0.9 and/or 20% decrease after a maximal treadmill test) suffering from intermittent
        claudication (Rutherford 1-3) presenting with new complaints (at least 6 months after
        previous revascularization) at the Vascular Center of university hospitals Leuven will be
        included if according to current guidelines their initial treatment should be conservative

        Inclusion Criteria:

          -  age &gt; 17 yrs

          -  ABI ≤0.9 and/or 20% decrease after a maximal treadmill test

          -  intermittent claudication (Rutherford 1-3)

          -  ability to undertake an exercise test and read and understand Dutch questionnaires

        Exclusion criteria

          -  exercise test induced signs of complex arrhythmias or significant ischemia during
             baseline testing

          -  other comorbidity limiting participation in the exercise group
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Véronique Cornelissen, PhD</last_name>
    <phone>016329152</phone>
    <email>veronique.cornelissen@kuleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>KU Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Cornelissen, PhD</last_name>
      <phone>003216329152</phone>
      <email>veronique.cornelissen@faber.kuleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 20, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Véronique Cornelissen</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

